| 货号 | AF4635-SP |
| 别名 | interleukin-28A; IFN-lambda 2; IL28A; IL-28A; interferon, lambda 2 | 全称 | Interleukin 28A |
| 反应种属 | Mouse |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects mouse IL‑28A/IFN‑ lambda 2 in direct ELISAs and Western blots. In Western blots, approximately 50% cross-reactivity with recombinant mouse IL‑28B is observed and less than 5% cross-reactivity with recombinant human (rh) IL-28A and rhIL-28B is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize IL‑28A/IFN‑ lambda 2 inhibition of EMCV-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The Neutralization Dose (ND50) is typically 3-15 µg/mL in the presence of 20 ng/mL Recombinant Mouse IL‑28A/IFN‑ lambda 2. |
| 来源 | Polyclonal Sheep IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 282616 (Human) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant mouse IL‑28A/IFN‑ lambda 2 Asp20-Val193 Accession # NP_001019844 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | IL-28A (also named interferon-lambda 2, IFN-lambda 2), IL-28B (IFN-lambda 3) and IL-29 (IFN-lambda 1) are type III interferons that are class II cytokine receptor ligands (1‑4). They are distantly related to members of the IL-10 family and type I IFN family (1‑4). Mouse IL-28A cDNA encodes a 193 amino acid (aa) protein with a 19 aa signal peptide and a 174 aa mature protein that lacks N-glycosylation sites. Mature mouse IL-28A shares 81% and 66% aa sequence identity with rat and human IL-28A, respectively, and functions across species (5). Mouse IL-28A and IL-28B share 97% aa identity; the mouse lacks a functional IL-29 gene (4). Type III interferons are widely expressed, but are mainly produced by antigen presenting cells in response to viruses and double-stranded RNA that interact with Toll-like receptors or RIG-1 family helicases (2‑6). They signal through a widely expressed receptor that is a heterodimer of the IL-10 receptor beta (IL-10 R beta ) and IL-28 receptor alpha (IL-28 R alpha ; also called IFN-lambda R1) (2, 3, 7, 9). Interaction of either type I or type III IFNs with their receptors activates similar pathways, including JAK tyrosine kinase activation, STAT phosphorylation and formation of the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex (1‑3). Both type I and III IFNs induce antiviral activity and upregulate MHC class I antigen expression (2‑6). Cell lines responsive to type III IFNs are also responsive to type I IFNs, but in general, higher concentrations of type III IFNs are needed for similar in vitro responses (8). In vivo, however, type III IFNs enhance levels of IFN-gamma in serum, suggesting that the robust antiviral activity of type III IFNs may stem in part from activation of the immune system (5, 7). Anti-proliferative and antitumor activity in vivo has also been shown for type III IFNs (9‑11). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IL‑28A/IFN‑ lambda 2 Inhibition of EMCV-induced Cytopathy and Neutralization by Mouse IL‑28A/IFN‑ lambda 2 Antibody. Recombinant Mouse IL‑28A (Catalog # 4635‑ML) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Mouse IL‑28A (20 ng/mL) is neutralized (green line) by increasing concentrations of Sheep Anti‑Mouse IL‑28A Antigen Affinity‑purified Polyclonal Antibody (Catalog # AF4635). The ND50 is typically 3‑15 µg/mL. |
